References
- Cairo MS. Dose reductions and delays: limitations of myelosuppressive chemotherapy. Oncology (Williston Park) 2000;14(Suppl. 8):21-31
- Demetri GD. Targeted approaches for the treatment of thrombocytopenia. Oncologist 2001;6(Suppl. 5):15-23
- PROMACTA® (eltrombopag). Full prescribing information. Research Triangle Park, NC, GlaxoSmithKline, 2008
- Erickson-Miller C, Delorme E, Giampa L, et al. Biological activity and selectivity for Tpo receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115. ASH Annual Meeting Abstracts 2004 November 16, 2004;104(11):2912
- Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 2009;2;27:424-30
- Erhardt JA, Erickson-Miller CL, Aivado M, et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009;37:1030-7
- Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739-41
- Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47
- McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36
- Guminski AD, Harnett PR, deFazio A. Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line – a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 2001;48:229-34
- Ishikawa H, Fujiwara K, Suzuki S, et al. Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients. Int J Clin Oncol 2002;7:330-3
- Pertusini E, Ratajczak J, Majka M, et al. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 2001;97:638-44
- Gibiansky E, Mudd JPN, Kamel YM. Population pharmacokinetics of eltrombopag in patients with cancer and healthy subjects. AAPS Journal 2009;11(S2): Abstract No 2498
- Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005;45:68-78
- Gianni L, Vigano L, Locatelli A. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997;15:1906-15
- Holmes FA, Madden T, Newman RA. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996;14:2713-21
- Farese AM, MacVittie TJ, Roskos L, et al. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF. Stem Cells 2003;21:79-89
- Vadhan-Raj S, Trent J, Araujo DM, et al. Evaluation of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): results of a phase I/II study. Abstract e20616. Presented at the 45th Annual Meeting of the American Society of Clinical Oncology. May 29 – June 2, 2009, Orlando, FL